Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Witberg, G; Codner, P; Landes, U; Brabanti, M; Valvo, R; De Backer, O; Ooms, JF; Sievert, K; El Sabbagh, A; Jimenez-Quevedo, P; Brennan, PF; Sedaghat, A; Masiero, G; Werner, P; Overtchouk, P; Watanabe, Y; Montorfano, M; Bijjam, VR; Hein, M; Fiorina, C; Arzamendi, D; Rodriguez-Gabella, T; Fernández-Vázquez, F; Baz, JA; Laperche, C; Grasso, C; Branca, L; Estévez-Loureiro, R; Benito-González, T; Santos, IJA; Ruile, P; Mylotte, D; Buzzatti, N; Piazza, N; Andreas, M; Tarantini, G; Sinning, JM; Spence, MS; Nombela-Franco, L; Guerrero, M; Sievert, H; Sondergaard, L; Van Mieghem, NM; Tchetche, D; Webb, JG; Kornowski, R.
Transcatheter Treatment of Residual Significant Mitral Regurgitation Following TAVR A Multicenter Registry
JACC-CARDIOVASC INTE. 2020; 13(23): 2782-2791. Doi: 10.1016/j.jcin.2020.07.014
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Andreas Martin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: OBJECTIVES The aim of this study was to describe baseline characteristics, and periprocedural and mid-term outcomes of patients undergoing transcatheter mitral valve interventions post-transcatheter aortic valve replacement (TAVR) and examine their clinical benefit. BACKGROUND The optimal management of residual mitral regurgitation (MR) post-TAVR is challenging. METHODS This was an international registry of 23 TAVR centers. RESULTS In total, 106 of 24,178 patients (0.43%) underwent mitral interventions post-TAVR (100 staged, 6 concomitant), most commonly percutaneous edge-to-edge mitral valve repair (PMVR). The median interval post-TAVR was 164 days. Mean age was 79.5 +/- 7.2 years, MR was >moderate in 97.2%, technical success was 99.1%, and 30-day device success rate was 88.7%. There were 18 periprocedural complications (16.9%) including 4 deaths. During a median follow-up of 464 days, the cumulative risk for 3-year mortality was 29.0%. MR grade and New York Heart Association (NYHA) functional class improved dramatically; at 1 year, MR was moderate or less in 90.9% of patients (mild or less in 69.1%), and 85.9% of patients were in NYHA functional class I/II. Staged PMVR was associated with lower mortality versus medical treatment (57.5% vs. 30.8%) in a propensity-matched cohort (n = 156), but this was not statistically significant (hazard ratio: 1.75; p = 0.05). CONCLUSIONS For patients who continue to have significant MR, remain symptomatic post-TAVR, and are anatomically suitable for transcatheter interventions, these interventions are feasible, safe, and associated with significant improvement in MR grade and NYHA functional class. These results apply mainly to PMVR. A staged PMVR strategy was associated with markedly lower mortality, but this was not statistically significant. (Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter Valve Registry [AMTRAC]; NCT04031274) (C) 2020 by the American College of Cardiology Foundation.
Find related publications in this database (Keywords): aortic stenosis; mitral regurgitation; TAVR; TMVR/r